Related Experiment Videos
Assessment of novel risk factors in patients at low risk for cardiovascular events based on Framingham risk
Jasmine Grewal1, Sammy Chan, Jiri Frohlich
1Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC.
Insights
Novel markers like flow-mediated dilation (FMD), hs-CRP, and s-ICAM-1 offer insights beyond the Framingham risk score for coronary heart disease (CHD) in low-risk individuals.
Area of Science:
- Cardiovascular Medicine
- Biomarkers
- Preventive Cardiology
Background:
- The Framingham risk score is a standard for coronary heart disease (CHD) risk assessment.
- It does not incorporate emerging "novel" markers.
- There is a need to evaluate these novel markers in low-risk populations.
Purpose of the Study:
- To assess the additive value of novel markers to the Framingham risk score for CHD risk.
- To investigate specific novel markers in a low-risk cohort.
- To identify markers that provide additional risk information.
Main Methods:
- Measured hs-CRP, s-VCAM, s-ICAM-1, e-selectin, homocysteine, and vWF.
- Assessed carotid intima-media thickness (IMT) and plaque presence via ultrasonography.
- Measured brachial ultrasound flow-mediated dilation (FMD) and calculated Framingham risk scores.
Main Results:
- High frequency of abnormal carotid IMT, plaques, hs-CRP, homocysteine, FMD, and s-ICAM-1 in the low-risk cohort.
- Average IMT, plaque count, and homocysteine correlated strongly with calculated CHD risk.
- hs-CRP, s-ICAM-1, and FMD were independent of the Framingham CHD risk calculation.
Conclusions:
- Flow-mediated dilation (FMD) reflects vascular functional status.
- hs-CRP and s-ICAM-1 indicate inflammatory processes.
- These markers (FMD, hs-CRP, s-ICAM-1) are independent of Framingham risk assessment in low-risk cardiovascular disease patients.
Background:
Coronary heart disease (CHD) risk assessed by the Framingham risk score does not take into account the various "novel" markers that are of increasing interest. In this paper we examine a low-risk population to determine which novel markers may be of additive value to the Framingham assessment of CHD risk.
Methods:
Levels of high-sensitivity C-reactive protein (hs-CRP), soluble vascular cell adhesion molecule (s-VCAM), soluble intercellular adhesion molecule (s-ICAM-1), endothelial selectin (e-selectin), homocysteine and von Willebrand factor (vWF) were measured in 53 apparently healthy subjects recruited from a risk-reduction referral clinic. Carotid intima medial thickness (IMT) and number of plaques were determined by ultrasonography. Brachial ultrasound flow-mediated dilation (FMD) was also measured. Framingham risk scores were calculated and univariate and multivariate analyses of the resulting percent CHD risk over 10 years and novel markers were undertaken.
Results:
Abnormal carotid IMT and presence of plaques, hs-CRP, homocysteine, FMD and s-ICAM-1 were detected with a high frequency in this low-risk cohort. Average IMT, number of plaques and homocysteine were highly correlated with the calculated percent CHD whereas measures of hs-CRP, s-ICAM-1 and FMD were independent of the percent CHD calculation.
Conclusions:
FMD, as a reflection of the functional status of the vasculature, and hs-CRP and s-ICAM-1, as indicators of inflammatory processes, were independent of Framingham risk assessment in patients at low risk for cardiovascular disease.
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Coronary Artery Disease I: Introduction
Heart Failure IV: Classification and Diagnostic Evaluation